# A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

> **NCT05759793** · PHASE1 · RECRUITING · sponsor: **Nanjing IASO Biotechnology Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma
- Plasma Cell Leukemia

## Interventions

- **DRUG:** CAR-GPRC5D

## Key facts

- **NCT ID:** NCT05759793
- **Lead sponsor:** Nanjing IASO Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-30
- **Primary completion:** 2025-09-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05759793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05759793, "A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05759793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*